NCT04911335 (FARINGEL-CP) is a Phase 2 clinical trial of Faringel plus and oral hygiene in Oral Mucositis, sponsored by Campus Bio-Medico University.

Who is sponsoring NCT04911335?

NCT04911335 is sponsored by Campus Bio-Medico University.

What drugs are being tested in NCT04911335?

Interventions in NCT04911335: Faringel plus and oral hygiene.

What condition does NCT04911335 study?

NCT04911335 studies Oral Mucositis.

Is NCT04911335 still recruiting?

NCT04911335 is currently completed. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT04911335: FARINGEL-CP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Propolis-based Product (FARINGEL PLUS) for Oral Mucositis in Palliative Care

Completed Phase 2 Last updated 8 February 2023

What this trial tests

Phase 2 trial testing Faringel plus and oral hygiene in Oral Mucositis in 77 participants. Completed in 7 November 2022.

Timeline

13 July 2021

Primary endpoint
7 November 2022

7 November 2022

Quick facts

Lead sponsor	Campus Bio-Medico University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	77
Start date	13 July 2021
Primary completion	7 November 2022
Estimated completion	7 November 2022
Sites	1 location across Italy

Drugs / interventions tested

Faringel plus and oral hygiene

Conditions studied

Oral Mucositis — all drugs for Oral Mucositis →

Sponsor

Campus Bio-Medico University

Who can join

18 and older, any sex, with Oral Mucositis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oral health is crucial for palliative patients' quality of life. The evidence on effective interventions and measures of oral mucositis in palliative care is sparse. This is a single-center, prospective, uncontrolled open label Phase 2 non-profit study, aimed at evaluating a propolis-based product (FARINGEL PLUS) added to basic oral hygiene safety, acceptability and activity in preventing and treating oral mucositis in patients in palliative care. A two-step design was adopted according to Simon's Optimum approach, with an overall sample of 77 evaluable cases (step1\_26 cases; step2\_51 cases).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Concordance of the World Health Organization, Oral Assessment Guide, and Tardieu Scales for Assessment of Oral Mucositis and Oral Disorders in Palliative Care Patients.
Mastroianni C, Marchetti A, Sguanci M, Amato S, et al · · 2025 · PMID 40197962 · DOI 10.1089/jpm.2024.0505
A Propolis-Based Protocol for Oral Health in Palliative Care: Results from a Phase II Trial.
Piredda M, Mastroianni C, Marchetti A, Sguanci M, et al · · 2025 · PMID 39711194 · DOI 10.1089/jpm.2024.0290

Verify or expand the search:

Other recruiting trials for Oral Mucositis

Currently open trials in the same condition.

NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
NCT07400328 — Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients · Phase 2 · recruiting
NCT06525402 — Effect of Sodium Bicarbonate, Saline and Black Mulberry Syrup on Degree of Oral Mucositis in Children Receiving Chemothe · NA · recruiting
NCT06315855 — F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors) · NA · recruiting
NCT05966194 — RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer · Phase 2 · recruiting

Other Campus Bio-Medico University trials

Trials by the same sponsor.

NCT07448350 — TENS for Restoring Somatotopic Sensory Feedback in Lower Limb Amputees and Improving Phantom Limb Perception · NA · not yet recruiting
NCT06860841 — Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM · Phase 4 · active not recruiting
NCT06834269 — Transcranial Static Magnetic Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sclerosis. · NA · recruiting
NCT06098040 — Long-Term Feedback Effect of FGM in Newly-Diagnosed T2D Patients · NA · active not recruiting
NCT05842148 — Quality of Life After Conservative Oncoplastic Surgery in Breast Cancer Patients (IRONY: lIfe afteR ONcoplastic surgerY) · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04911335 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Campus Bio-Medico University
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04911335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing